ProMIS Neurosciences Inc. (PMN): Total Assets
$9.18M
As of 2025-12-31
$56.69M
As of 2026-06-30
+9.9%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.18M | -51.4% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $18.91M | +38.9% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $13.62M | +96.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $6.92M | -61.0% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $17.75M | n/a | 2023-03-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | $9.18M | -51.4% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $9.24M | +3.0% |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $9.31M | +26.9% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $8.97M | +26.9% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $9.49M | -82.9% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $9.51M | +4.3% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $8.82M | -31.2% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $9.62M | -41.5% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $8.75M | -11.7% |
Compare PMN, SNGX, INDP, ETST side by side · Screen every company in Pharmaceutical Preparations ↗